Core Viewpoint - The stock price of Haoyuan Pharmaceutical has shown fluctuations, with a recent decline of 2.02% and a year-to-date increase of 16.01%, indicating volatility in market performance [1][2]. Company Overview - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, is located in Shanghai and specializes in the research and development of small molecule drug discovery, including molecular building blocks and tool compounds [2]. - The company provides products and technical services for global pharmaceutical enterprises and research institutions, covering the entire process from drug discovery to the large-scale production of active pharmaceutical ingredients and intermediates [2]. Financial Performance - For the period from January to September 2025, Haoyuan Pharmaceutical achieved a revenue of 2.059 billion yuan, representing a year-on-year growth of 27.18%, and a net profit attributable to shareholders of 237 million yuan, reflecting a significant increase of 65.09% [2]. - The company has distributed a total of 160 million yuan in dividends since its A-share listing, with 120 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Haoyuan Pharmaceutical was 12,000, a decrease of 6.34% from the previous period, with an average of 17,647 circulating shares per person, an increase of 6.77% [2]. - Notable shareholders include Hong Kong Central Clearing Limited, which holds 8.6068 million shares, and several mutual funds that have increased their holdings [3].

Core Insights - On November 14, Haoyuan Pharmaceutical experienced a decline of 3.54% with a trading volume of 242 million yuan [1] - The company reported a financing buy-in of 32.97 million yuan and a net financing buy of 6.87 million yuan on the same day [1] Financing Overview - As of November 14, the total financing and securities balance for Haoyuan Pharmaceutical was 592 million yuan [1] - The financing balance of 591 million yuan accounts for 3.61% of the circulating market value, indicating a high level compared to the past year [1] - The company had a low securities lending balance of 96.21 million yuan, below the 50th percentile of the past year [1] Company Profile - Haoyuan Pharmaceutical, established on September 30, 2006, is located in Shanghai and specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds [2] - The company's main revenue sources include molecular building blocks and tool compounds (68.97%), with product sales contributing 63.42% and raw materials and intermediates accounting for 30.46% [2] - For the period from January to September 2025, Haoyuan Pharmaceutical achieved a revenue of 2.059 billion yuan, representing a year-on-year growth of 27.18%, and a net profit of 237 million yuan, up 65.09% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Haoyuan Pharmaceutical was 12,000, a decrease of 6.34% from the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several mutual funds, with notable increases in holdings [3]

Core Insights - Haoyuan Pharmaceutical experienced a 5.2% increase in stock price, reaching 78.51 CNY per share, with a trading volume of 313 million CNY and a turnover rate of 1.94%, resulting in a total market capitalization of 16.652 billion CNY [1] Company Overview - Shanghai Haoyuan Pharmaceutical Co., Ltd. was established on September 30, 2006, and went public on June 8, 2021. The company specializes in the discovery of small molecule drugs, focusing on molecular building blocks and tool compounds, as well as the development and production of active pharmaceutical ingredients (APIs) and intermediates [1] - The main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents at 68.97%, with product sales contributing 63.42%, APIs and intermediates at 30.46%, technical services at 5.55%, and other supplementary services at 0.57% [1] Fund Holdings - According to data, one fund under GF Fund has a significant holding in Haoyuan Pharmaceutical. The GF Medical Selected Stock A (017479) held 39,000 shares in the third quarter, accounting for 5.25% of the fund's net value, ranking as the eighth largest holding [2] - The GF Medical Selected Stock A (017479) was established on July 6, 2023, with a latest scale of 41.6154 million CNY. Year-to-date returns stand at 44.25%, ranking 797 out of 4216 in its category, while the one-year return is 37.56%, ranking 854 out of 3909 [2] Fund Manager Profile - The fund manager of GF Medical Selected Stock A (017479) is Wang Ruidong, who has been in the position for 5 years and 172 days. The total asset scale of the fund is 4.817 billion CNY, with the best fund return during his tenure being 59.03% and the worst at -12.32% [3]

Core Insights - The CXO (Contract Research Organization) sector in A-shares has shown strong growth, with 20 out of 29 listed companies reporting year-on-year revenue increases in the first three quarters [1] - The third quarter alone saw 21 companies achieving revenue growth compared to the same period last year, driven by international demand for innovative drugs [1] - The sector is benefiting from both policy support and a surge in demand, which is enhancing new drug development needs and positively impacting the CXO industry [1] Policy Support - The National Healthcare Security Administration and the National Health Commission issued measures on July 1 to support the high-quality development of innovative drugs, outlining 16 policies to enhance the entire chain of support for innovative drug development [1] Demand Growth - Several CXO companies reported robust order backlogs for the first three quarters. For instance, WuXi AppTec reported a backlog of 59.88 billion yuan, a 41.2% increase year-on-year [1] - Kanglong Chemical indicated a more than 13% year-on-year growth in new orders, with acceleration in growth compared to the first half of the year [1] - Yino Science reported a nearly 20% increase in order amounts compared to the end of 2024 [2] - Haoyuan Pharmaceutical noted a 50% year-on-year increase in its small molecule business orders, marking four consecutive quarters of growth [2] Internationalization and Market Trends - The first half of the year saw a significant increase in the internationalization of Chinese innovative drugs, with total external authorization transactions reaching 60 billion USD, accounting for 99% of global related transactions [2] - Morgan Stanley's healthcare research head for Greater China anticipates stable long-term growth in external authorization transactions, with multinational companies likely to be more active in acquiring Chinese innovative drug assets [2] - The CXO industry is transitioning from a "scale dividend" to a "technology premium," with technological iteration and process innovation becoming the core of industry competition [2]

Core Insights - Shanghai Haoyuan Pharmaceutical Co., Ltd. reported a revenue of 2.06 billion yuan for the first three quarters of 2025, marking a year-on-year increase of 27.2%, and a net profit attributable to shareholders of 240 million yuan, up 65.1% year-on-year [2] - The company achieved a comprehensive gross margin of 49.7%, an increase of 2.2 percentage points compared to the previous year [2] - The company’s front-end life science reagent business generated 1.45 billion yuan in revenue, growing over 31.0% year-on-year, accounting for over 70% of the company's main business revenue [2] Business Segments - The front-end life science reagent business is thriving, with over 13,000 global partners and significant revenue growth [2] - The back-end business, focusing on high-difficulty and high-barrier specialty technologies, achieved 600 million yuan in revenue, a year-on-year increase of 16.9% [2] - The back-end small molecule business has an order backlog of 630 million yuan, reflecting a 50% year-on-year increase and consistent quarter-on-quarter growth for four consecutive quarters [2] Technological Advancements - The company has developed an integrated service platform for ADC payload-linker CMC and established a comprehensive service system centered in Shanghai, Ma'anshan, and Chongqing, successfully undertaking over 90 ADC projects in the first three quarters [3] - Haoyuan Pharmaceutical is leveraging its extensive high-value data to integrate AI technology into drug development, creating a one-stop drug screening platform that offers various screening technologies and optimization services [3] Future Outlook - The company anticipates that the innovation wave in the biopharmaceutical industry and global market opportunities will provide significant growth potential [4] - With ongoing synergy across business segments and deep integration of cutting-edge technologies and industry resources, the company aims to expand its competitive edge in innovative drug services [4] - The long-term strategy focuses on globalization and technological iteration to seize industry transformation opportunities and contribute more value to pharmaceutical innovation [4]

Group 1 - The core viewpoint of the news is that Haoyuan Pharmaceutical's stock has seen a significant increase, with a rise of 5.06% to 76.38 CNY per share, and a total market capitalization of 16.2 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds, as well as the production and technical improvement of active pharmaceutical ingredients and intermediates [1] - The company's main business revenue composition includes 68.97% from molecular building blocks, tool compounds, and biochemical reagents, with product sales contributing 63.42%, active pharmaceutical ingredients and intermediates 30.46%, technical services 5.55%, and other sources 0.57% [1] Group 2 - According to data, Guotai Fund holds Haoyuan Pharmaceutical as a significant investment, with the Guotai Innovation Medical Mixed Fund A (018159) holding 14,000 shares, accounting for 3.93% of the fund's net value, ranking as the seventh largest holding [2] - The Guotai Innovation Medical Mixed Fund A was established on April 18, 2023, with a latest scale of 12.614 million CNY, and has achieved a year-to-date return of 50.31%, ranking 623 out of 8161 in its category [2] - The fund manager, Qiu Xiaoxu, has a tenure of 3 years and 62 days, with the fund's total asset size at 871 million CNY, achieving a best return of 19.63% and a worst return of 0.83% during the tenure [3]

Group 1 - The core point of the article highlights the recent decline in the stock price of Haoyuan Pharmaceutical, which fell by 5.05% to 76.91 CNY per share, with a trading volume of 178 million CNY and a turnover rate of 1.07%, resulting in a total market capitalization of 16.313 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds, as well as the process development and production technology improvement of active pharmaceutical ingredients (APIs) and intermediates [1] - The company's main business revenue composition includes 68.97% from molecular building blocks, tool compounds, and biochemical reagents, with product sales accounting for 63.42%, APIs and intermediates contributing 30.46%, and technical services making up 5.55% [1] Group 2 - From the perspective of fund holdings, Haoyuan Pharmaceutical is a significant position in the Hongta Hongtu Fund, specifically in the Hongta Hongtu Medical Selected Stock A Fund (020331), which holds 13,000 shares, representing 4.93% of the fund's net value, ranking as the fourth-largest holding [2] - The Hongta Hongtu Medical Selected Stock A Fund (020331) was established on April 2, 2024, with a latest scale of 11.6663 million CNY, achieving a year-to-date return of 32.35%, ranking 1626 out of 4220 in its category, and a one-year return of 20.3%, ranking 2324 out of 3855 [2]

Group 1 - The core viewpoint of the news is that Haoyuan Pharmaceutical has seen a stock price increase of 5.07% as of September 30, reaching 81.60 CNY per share, with a total market capitalization of 17.307 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, specializes in the research and development of molecular building blocks and tool compounds in the small molecule drug discovery field, as well as the process development and production technology improvement of active pharmaceutical ingredients (APIs) and intermediates [1] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents at 68.97%, with product sales contributing 63.42%, APIs and intermediates at 30.46%, technical services at 5.55%, and other sources at 0.57% [1] Group 2 - From the perspective of fund holdings, Haoyuan Pharmaceutical is a top ten holding of the Hengsheng Qianhai Fund, specifically in the Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332), which held 24,600 shares, accounting for 2.1% of the fund's net value [2] - The fund has achieved a year-to-date return of 39.78%, ranking 2105 out of 8167 in its category, and a one-year return of 45.37%, ranking 2370 out of 8010 [2] Group 3 - The fund manager of Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332) is Xing Cheng, who has been in the position for 3 years and 193 days, with the fund's total asset size at 252 million CNY [3] - During Xing Cheng's tenure, the best fund return was 87.69%, while the worst return was -29.15% [3]

近日，上海皓元医药股份有限公司发布股东减持股份结果公告，披露了股东苏民投君信（上海）产业升 级与科技创新股权投资合伙企业（有限合伙）（简称"苏信基金"）减持计划的实施情况。 减持前持股情况 减持计划实施前，苏信基金持有皓元医药6,909,364股股份，占减持计划实施前公司总股本的3.26%。这 些股份来源于公司首次公开发行前及上市后权益分派资本公积转增股本，且已上市流通。 减持计划及实施结果 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 2025年8月7日，皓元医药在上海证券交易所网站披露苏信基金减持股份计划公告。苏信基金拟通过集中 竞价或大宗交易方式，减持不超过6,362,959股公司股份，拟减持比例不超过减持计划实施前公司总股本 的3.00 ...

Core Viewpoint - Haoyuan Pharmaceutical experienced a 5.1% increase in stock price, reaching 74.00 CNY per share, with a total market capitalization of 15.695 billion CNY as of September 12 [1] Company Overview - Shanghai Haoyuan Pharmaceutical Co., Ltd. was established on September 30, 2006, and went public on June 8, 2021. The company specializes in the discovery of small molecule drugs, focusing on molecular building blocks and tool compounds, as well as the development and production of active pharmaceutical ingredients (APIs) and intermediates [1] - The main revenue sources for the company include molecular building blocks, tool compounds, and biochemical reagents, accounting for 68.97% of total revenue. Product sales contribute 63.42%, while APIs and intermediates, along with formulations, account for 30.46%. Technical services make up 5.55%, and other sources contribute 0.57% [1] Shareholder Information - Among the top circulating shareholders of Haoyuan Pharmaceutical, a fund under China Europe Fund holds a significant position. The China Europe Healthcare Mixed A Fund (003095) reduced its holdings by 2.7776 million shares in the second quarter, retaining 6.1185 million shares, which represents 2.97% of the circulating shares. The estimated floating profit from this transaction is approximately 21.9653 million CNY [2] - The China Europe Healthcare Mixed A Fund was established on September 29, 2016, with a current scale of 15.638 billion CNY. Year-to-date returns stand at 31.02%, ranking 2473 out of 8174 in its category, while the one-year return is 47.65%, ranking 3246 out of 7981. Since its inception, the fund has achieved a return of 126.12% [2] Fund Management - The fund manager of China Europe Healthcare Mixed A is Ge Lan, who has been in the position for 10 years and 230 days, overseeing assets totaling 39.908 billion CNY, with the best fund return during her tenure being 126.12% and the worst being -35.13% [3] - Co-manager Zhao Lei has been in the role for 71 days, managing assets of 30.801 billion CNY, with the best return being 17.59% and the worst being 17.42% during his tenure [3]